MX2023007524A - Composiciones y metodos para edicion epigenetica. - Google Patents

Composiciones y metodos para edicion epigenetica.

Info

Publication number
MX2023007524A
MX2023007524A MX2023007524A MX2023007524A MX2023007524A MX 2023007524 A MX2023007524 A MX 2023007524A MX 2023007524 A MX2023007524 A MX 2023007524A MX 2023007524 A MX2023007524 A MX 2023007524A MX 2023007524 A MX2023007524 A MX 2023007524A
Authority
MX
Mexico
Prior art keywords
compositions
methods
epigenetic
epigenetic editing
editing
Prior art date
Application number
MX2023007524A
Other languages
English (en)
Inventor
Morgan Maeder
Ari Friedland
Samantha Linder
Vic Myer
Original Assignee
Chroma Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chroma Medicine Inc filed Critical Chroma Medicine Inc
Publication of MX2023007524A publication Critical patent/MX2023007524A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/01—Methyltransferases (2.1.1)
    • C12Y201/01037—DNA (cytosine-5-)-methyltransferase (2.1.1.37)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En la presente se divulgan composiciones y métodos que comprenden editores epigenéticos para edición epigenética o células, ácidos nucleicos y vectores que comprenden los mismos. También se divulgan cromosomas epigenéticamente modificados.
MX2023007524A 2020-12-22 2021-12-22 Composiciones y metodos para edicion epigenetica. MX2023007524A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063129283P 2020-12-22 2020-12-22
US202163280452P 2021-11-17 2021-11-17
PCT/US2021/064913 WO2022140577A2 (en) 2020-12-22 2021-12-22 Compositions and methods for epigenetic editing

Publications (1)

Publication Number Publication Date
MX2023007524A true MX2023007524A (es) 2023-09-19

Family

ID=82160095

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007524A MX2023007524A (es) 2020-12-22 2021-12-22 Composiciones y metodos para edicion epigenetica.

Country Status (10)

Country Link
US (1) US20240076678A1 (es)
EP (1) EP4267743A2 (es)
JP (1) JP2024501383A (es)
KR (1) KR20240011120A (es)
AU (1) AU2021409729A1 (es)
CA (1) CA3202977A1 (es)
GB (1) GB2619423A (es)
IL (1) IL303923A (es)
MX (1) MX2023007524A (es)
WO (1) WO2022140577A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023215711A1 (en) * 2022-05-01 2023-11-09 Chroma Medicine, Inc. Compositions and methods for epigenetic regulation of pcsk9 expression
WO2023250511A2 (en) 2022-06-24 2023-12-28 Tune Therapeutics, Inc. Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
WO2024015881A2 (en) * 2022-07-12 2024-01-18 Tune Therapeutics, Inc. Compositions, systems, and methods for targeted transcriptional activation
WO2024044572A1 (en) * 2022-08-23 2024-02-29 The Regents Of The University Of California Modified dna binding proteins and methods of use thereof
WO2024044574A1 (en) * 2022-08-23 2024-02-29 The Regents Of The University Of California Compositions and methods for reducing ionizing radiation-induced hematopoietic stem cell damage
WO2024064910A1 (en) * 2022-09-23 2024-03-28 Chroma Medicine, Inc. Compositions and methods for epigenetic regulation of hbv gene expression
WO2024081879A1 (en) * 2022-10-14 2024-04-18 Chroma Medicine, Inc. Compositions and methods for epigenetic regulation of cd247 expression
WO2024131940A1 (zh) * 2022-12-23 2024-06-27 益杰立科(上海)生物科技有限公司 融合物及其用途
WO2024145615A2 (en) * 2022-12-30 2024-07-04 Chroma Medicine, Inc. Compositions and methods for epigenetic regulation of angptl3 expression
WO2024158777A1 (en) * 2023-01-23 2024-08-02 The General Hospital Corporation Methods and compositions for inhibiting suppression of anti-tumor immunity by targeting ligand-receptor interactions present in the placenta
WO2024178628A1 (en) * 2023-02-28 2024-09-06 Sun Yat-Sen University Epigenetic editor assisted by phase separation proteins
WO2024206565A1 (en) * 2023-03-29 2024-10-03 Scribe Therapeutics Inc. Repressor fusion protein systems

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
JP5723774B2 (ja) 2008-09-05 2015-05-27 プレジデント アンド フェローズ オブ ハーバード カレッジ タンパク質および核酸の連続的指向性進化
LT2566972T (lt) 2010-05-03 2020-03-10 Sangamo Therapeutics, Inc. Kompozicijos, skirtos cinko pirštu modulių susiejimui
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
WO2016011070A2 (en) 2014-07-14 2016-01-21 The Regents Of The University Of California A protein tagging system for in vivo single molecule imaging and control of gene transcription
GB201418965D0 (es) * 2014-10-24 2014-12-10 Ospedale San Raffaele And Fond Telethon
JP6929791B2 (ja) * 2015-02-09 2021-09-01 デューク ユニバーシティ エピゲノム編集のための組成物および方法
JP6500293B2 (ja) 2015-11-25 2019-04-17 国立大学法人群馬大学 Ｄｎａメチル化編集用キットおよびｄｎａメチル化編集方法
WO2018035495A1 (en) * 2016-08-19 2018-02-22 Whitehead Institute For Biomedical Research Methods of editing dna methylation
WO2018049077A1 (en) * 2016-09-07 2018-03-15 Flagship Pioneering, Inc. Methods and compositions for modulating gene expression
KR20190072548A (ko) 2016-09-30 2019-06-25 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Rna-가이드된 핵산 변형 효소 및 이의 사용 방법
AU2017335890B2 (en) 2016-09-30 2024-05-09 The Regents Of The University Of California RNA-guided nucleic acid modifying enzymes and methods of use thereof
EP3538561A4 (en) 2016-11-11 2020-10-21 The Regents of The University of California RNA-GUIDED POLYPEPTIDE VARIANTS AND METHOD OF USING
BR112019021719A2 (pt) * 2017-04-21 2020-06-16 The General Hospital Corporation Variantes de cpf1 (cas12a) com especificidade para pam alterada
US20200255858A1 (en) 2017-11-01 2020-08-13 Jillian F. Banfield Casy compositions and methods of use
EP3781705A4 (en) * 2018-04-19 2022-01-26 The Regents of the University of California COMPOSITIONS AND METHODS FOR GENE EDITING
SG11202011975WA (en) 2018-06-05 2020-12-30 Lifeedit Inc Rna-guided nucleases and active fragments and variants thereof and methods of use
WO2020023529A1 (en) * 2018-07-24 2020-01-30 The Regents Of The University Of California Rna-guided nucleic acid modifying enzymes and methods of use thereof
EP3841205A4 (en) 2018-08-22 2022-08-17 The Regents of The University of California VARIANT TYPE CRISPR/CAS V EFFECTIVE POLYPEPTIDES AND METHODS OF USE THEREOF

Also Published As

Publication number Publication date
WO2022140577A2 (en) 2022-06-30
GB2619423A (en) 2023-12-06
GB202311318D0 (en) 2023-09-06
IL303923A (en) 2023-08-01
AU2021409729A1 (en) 2023-07-13
JP2024501383A (ja) 2024-01-11
KR20240011120A (ko) 2024-01-25
EP4267743A2 (en) 2023-11-01
WO2022140577A3 (en) 2022-11-03
US20240076678A1 (en) 2024-03-07
CA3202977A1 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
MX2023007524A (es) Composiciones y metodos para edicion epigenetica.
MX2021003457A (es) Composiciones y métodos para la edición génica de lactato deshidrogenasa (ldha).
PH12021550904A1 (en) Novel crispr/cas12f enzyme and system
MX2021005723A (es) Enzima y sistema crispr-cas12j.
WO2020051562A3 (en) Compositions and methods for improving base editing
WO2018191715A3 (en) Polypeptides with type v crispr activity and uses thereof
WO2019089884A3 (en) Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
CA3139122A1 (en) Curing for recursive nucleic acid-guided cell editing
EP4321617A3 (en) Crispr/cpf1 systems and methods
WO2020081149A3 (en) Improved detection of nuclease edited sequences in automated modules and instruments
AU2018339089A1 (en) Polynucleotides, compositions, and methods for genome editing
WO2018175502A3 (en) Treating cancer with cas endonuclease complexes
MX2021001070A (es) Composiciones y métodos para editar el gen hidroxiácido oxidasa 1 (hao1) para tratar la hiperoxaluria primaria tipo 1 (ph1).
WO2021231691A8 (en) Methods and compositions for the adar-mediated editing of retinoschisin 1 (rs1)
WO2017027423A9 (en) Engineered crispr-cas9 compositions and methods of use
WO2017070633A3 (en) Evolved cas9 proteins for gene editing
MX2022007575A (es) Anticuerpos anti cumulo de diferenciacion 73 (cd73) y usos de estos.
WO2021055459A8 (en) Highly efficient dna base editors mediated by rna-aptamer recruitment for targeted genome modification and uses thereof
MX2020003339A (es) Arn guía de cpf1 modificado.
MX2021014528A (es) Metodos y composiciones para generar alelos dominantes usando edicion del genoma.
WO2022051020A9 (en) Systems, methods, and compositions for rna-guided rna-targeting crispr effectors
WO2020003006A3 (en) Compositions and methods for genomic editing by insertion of donor polynucleotides
AU2021216418A8 (en) Compositions and methods for targeting, editing or modifying human genes
MX2024003007A (es) Sistemas crispr de clase ii, tipo v.
MX2022009658A (es) Composiciones y metodos para la edicion de genes de calicreina (klkb1).